The Impact of Vaccination Against SARS-CoV-2 Virus on the Outcome of COVID-19 Disease

Background Coronavirus disease 2019 (COVID-19) is a rapidly spreading infection that is on the rise. New variants are continuously appearing with variable degrees of lethality and infectivity. The extensive work since the start of the pandemic has led to the evolution of COVID-19 vaccines with varying mechanisms. We aim to determine real-world data by looking at the different clinical outcomes associated with COVID-19 vaccination, focusing on the rate of hospitalization, severity, and mortality. Methodology A retrospective observational study included 624 patients with COVID-19 infection who were hospitalized at King Fahad Hospital of the University and King Fahad Military Medical City between April and July 2021. The cohort was divided into 3 groups: unvaccinated, partially vaccinated (PV), and fully vaccinated (FV). The severity and outcome of COVID-19 disease were compared among the three groups. Among the vaccinated group, we studied the effect of vaccine type on the severity and outcome of COVID-19 disease. Results We found that 70.4% of patients with COVID-19 disease who required hospitalization were unvaccinated. Un-vaccination was a significant predictor of critical COVID-19 disease (OR 2.31; P <0.001), whereas full vaccination was associated with significantly milder disease severity (OR 0.36; P 0.01). Moreover, un-vaccination status was an independent predictor of longer hospitalization (OR 3.0; P <0.001), a higher requirement for ICU admission (OR 4.7; P <0.001), mechanical ventilation (OR 3.6; P <0.001), and death (OR 4.8; P <0.001), whereas the FV group had a lower risk of ICU admission (OR 0.49; P 0.045). Unvaccinated patients with comorbidities had worse severity and outcome of COVID-19 infection (P<0.05). Both vaccine types (Pfizer and AstraZeneca) had similar protective effects against the worst outcomes of COVID-19 disease. Conclusion COVID-19 vaccination has been shown to be effective in reducing hospitalization, the severity of COVID-19 infection, and improving outcomes, especially in high-risk group patients. COVID-19 vaccination programs should continue to improve the outcome of such a disease.

[1]  J. Mayet,et al.  Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum , 2022, eClinicalMedicine.

[2]  T. Loney,et al.  Impact of Age and Sex on COVID-19 Severity Assessed From Radiologic and Clinical Findings , 2022, Frontiers in Cellular and Infection Microbiology.

[3]  Manish M Patel,et al.  Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents , 2022, The New England Journal of Medicine.

[4]  M. Kamal,et al.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic , 2022, Environmental Research.

[5]  M. Exline,et al.  Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. , 2021, JAMA.

[6]  M. Verma,et al.  Effectiveness of COVID-19 vaccine in preventing infection and disease severity: a case-control study from an Eastern State of India , 2021, Epidemiology and Infection.

[7]  Z. Memish,et al.  Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: A prospective observational study , 2021, Annals of Medicine and Surgery.

[8]  G. Maine,et al.  Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study , 2021, The Lancet Regional Health - Americas.

[9]  Haiyan Yang,et al.  A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity , 2021, BMC Public Health.

[10]  C. Robertson,et al.  Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study , 2021, BMJ.

[11]  D. Swerdlow,et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.

[12]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[13]  Z. B. Taha,et al.  WITHDRAWN: D-Dimer and Serum Ferritin as an Independent Risk Factor for Severity in COVID-19 Patients , 2021, Materials Today: Proceedings.

[14]  H. Alwafi,et al.  Predictors of Length of Hospital Stay, Mortality, and Outcomes Among Hospitalised COVID-19 Patients in Saudi Arabia: A Cross-Sectional Study , 2021, Journal of multidisciplinary healthcare.

[15]  P. Marik,et al.  Gender‐based disparities in COVID-19 patient outcomes , 2021, Journal of Investigative Medicine.

[16]  Kok-Gan Chan,et al.  COVID-19: Insights into Potential Vaccines , 2021, Microorganisms.

[17]  B. Singer,et al.  The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[19]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[20]  Carlos Dornels Freire de Souza,et al.  Clinical manifestations of COVID-19 in the general population: systematic review , 2020, Wiener klinische Wochenschrift.

[21]  E. Kenigsberg,et al.  Gastrointestinal involvement attenuates COVID-19 severity and mortality , 2020, medRxiv.

[22]  Mario Plebani,et al.  Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis , 2020, The American Journal of Emergency Medicine.

[23]  R. Pranata,et al.  Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[24]  Fang Liu,et al.  Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 , 2020, Journal of Clinical Virology.

[25]  A. Oommen,et al.  Epidemiology of COVID-19 , 2020, Journal of Digestive Endoscopy.

[26]  J. Ehreth.  The global value of vaccination. , 2003, Vaccine.